Pharmacological control of autophagy: Therapeutic perspectives in inflammatory bowel disease and colorectal cancer

Current Pharmaceutical Design

Volumn 18, Issue 26, 2012, Pages 3853-3873

  García Mauriño, Sofía ^a   Alcaide, Antonio ^a   Domínguez, Cecilia ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

AMP dependent kinase; Autophagy; Colorectal cancer; Endoplasmic Reticulum stress; Inflammatory bowel disease; Mammalian target of rapamycin

Indexed keywords

ACTIVATED TRANSCRIPTION FACTOR 6; AUTOPHAGY RELATED PROTEIN 16; BAFILOMYCIN A1; BECLIN 1; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CETUXIMAB; CYTOKINE; EVEROLIMUS; FLUOROURACIL; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSITOL REQUIRING TRANSMEMBRANE KINASE ENDORIBONUCLEASE 1; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PANCREATIC ER KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN; PROTEIN BCL 2; PROTEIN P53; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SIRTUIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOTAROLIMUS;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CATALYSIS; CELL FUNCTION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; CPG ISLAND; DNA POLYMORPHISM; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE THERAPY; GENETIC ASSOCIATION; GOBLET CELL; HEREDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE EPITHELIUM; MICROSATELLITE INSTABILITY; MITOCHONDRION; MUTATION; NONHUMAN; OXIDATIVE STRESS; PANETH CELL; PEROXISOME; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION; UNFOLDED PROTEIN RESPONSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; MOLECULAR TARGETED THERAPY;

EID: 84864544220     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802083653     Document Type: Review

References (316)

1. Takeshige K, Baba M, Tsuboi S, Noda T, Ohsumi Y. Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction. J Cell Biol 1992; 119: 301-11.
2. Huang WP, Klionsky DJ. Autophagy in yeast: a review of the molecular machinery. Cell Struct Funct 2002; 27: 409-20.
3. Sigmond T, Barna J, Tóth ML, et al. Autophagy in Caenorhabditis elegans. Methods Enzymol 2008; 451: 521-40.
4. Tian Y, Li Z, Hu W, et al. C. elegans screen identifies autophagy genes specific to multicellular organisms. Cell 2010; 141: 1042-55.
5. Baehrecke EH. Autophagic programmed cell death in Drosophila. Cell Death Differ 2003; 10: 940-5.
6. McPhee CK, Baehrecke EH. Autophagy in Drosophila melanogaster. Biochim Biophys Acta 2009; 1793: 1452-60.
7. Kim J, Klionsky DJ. Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells. Annu Rev Biochem 2000; 69: 303-42.
8. Fimia GM, Piacentini M. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci 2010; 67: 1581-8.
9. Bassham DC. Function and regulation of macroautophagy in plants. Biochim Biophys Acta 2009; 1793: 1397-403.
10. Yoshimoto K, Takano Y, Sakai Y. Autophagy in plants and phytopathogens. FEBS Lett 2010; 584: 1350-8.
11. Klionsky DJ, Cregg JM, Dunn WA, et al. A unified nomenclature for yeast autophagy-related genes. Dev Cell 2003; 5: 539-45.
12. Yan Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol 2009; 335: 1-32.
13. Uchiyama Y, Shibata M, Koike M, Yoshimura K, Sasaki M. Autophagy-physiology and pathophysiology. Histochem Cell Biol 2008; 129: 407-20.
14. Klionsky DJ, Codogno P, Cuervo AM, et al. A comprehensive glossary of autophagy-related molecules and processes. Autophagy 2010; 6: 438-48.
15. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010; 466: 68-76.
16. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol 2000; 150: 1507-13.
17. Hosokawa N, Hara T, Kaizuka T, et al. Nutrientdependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009; 20: 1981-91.
18. Jung CH, Jun CB, Ro SH, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009; 20: 1992-2003.
19. Mercer CA, Kaliappan A, Dennis PB. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. Autophagy 2009; 5: 649-62.
20. Mizushima N. The role of the Atg/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22, 132-9.
21. Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy 2010; 6: 764-76.
22. Funderburk SF, Wang QJ, Yue Z. The Beclin1-VPS34 complex-at the crossroads of autophagy and beyond. Trends Cell Biol 2010; 20: 355-62.
23. Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res 2007; 17: 839-49.
24. Yan Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Cur Opin Cell Biol 2010; 22: 124-31.
25. Ohsumi, Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol 2001; 2: 211-6.
26. Kuma A, Mizushima N, Ishihara N, Ohshumi Y. Formation of the -350-kDa Apg12-Apg5·Apg16 multimeric complex, mediated by Apg16 oligomerization, is essential for autophagy in yeast. J Biol Chem 2002; 277: 18619-25.
27. Mizushima N, Sugita H, Yoshimori T, Ohsumi Y. A new protein conjugation system in human the counterpart of the yeast Apg12p conjugation system essential for autophagy. J Biol Chem 1998; 273: 33889-92.
28. Mizushima N, Kuma A, Kobayasi Y, et al. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J Cell Sci 2003; 116: 1679-88.
29. Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy 2007; 3: 649-51.
30. Suzuki K, Kirisako T, Kamada Y, Mizushima N, Noda T, Oshumi Y. The pre-autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formation. EMBO J 2001; 20: 5971-81.
31. Hanada T, Noda NN, Satomi Y, et al. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. EMBO J 2007; 282: 37298-302.
32. Fujita N, Itoh T, Omori H, Fukuda M, Noda T, Yoshimori T. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell 2008; 19: 2092-100.
33. Kirisako T, Baba M, Ishihara N, et al. Formation process of autophagosome is traced with Apg8/Aut7p in yeast. J Cell Biol 1999; 147: 435-46.
34. Ichimura Y, Kirisako T, TakaoT, et al. A ubiquitin-like system mediates protein lipidation. Nature 2000; 408: 488-92.
35. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-8.
36. Mann SS, Hammarback JA. Molecular characterization of light chain 3. A microtubule binding subunit of MAP1A and MAP1B. J Biol Chem 1994; 269: 11492-7.
37. Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-75.
38. Legakis JE, Yen WL, Klionsky DJ. A cycling protein complex required for selective autophagy. Autophagy 2007; 3: 422-32.
39. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. J Mol Cel 2010; 40: 280-93.
40. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30: 678-88.
41. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-95.
42. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-57.
43. Shaw R J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196: 65-80.
44. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-26.
45. Høyer-Hansen M, Bastholm L, Szyniarowski P, et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinaseb, and Bcl-2. Mol Cell 2007; 25: 193-205.
46. Herrero-Martin G, Høyer-Hansen M, Garcia-Garcia C, et al. TAK1 activates AMPKdependent cytoprotective autophagy in TRAILtreated epithelial cells. EMBO J 2009; 28: 677-85.
47. Papandreou I, Lim AL, Laderoute K, Denko NC. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ 2008; 15: 1572-81.
48. Shang L, Wang X. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. Autophagy 2011; 7: 924-6.
49. Lu SP, Lin SJ. Regulation of yeast sirtuins by NAD+ metabolism and calorie restriction. Biochim Biophys Acta 2010; 1804: 1567-75.
50. Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: linking NAD+ metabolism and signalling to the con trol of cellular functions. Biochim Biophys Acta 2010; 1804: 1666-75.
51. Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-60.
52. Lee IH, Cao L, Mostoslavsky R, et al. A role for the NADdependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 2008; 105: 3374-9.
53. Lan F, Caciedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008; 283: 27628-35.
54. Balaburski GM, Hontz RD, Murphy ME. p53 and ARF: unexpected players in autophagy. Trends Cell Biol 2010; 20: 363-9.
55. Maiuri MC, Galluzzi L, Morselli E Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22: 181-185.
56. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation ofthe p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102: 8204-9.
57. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-34.
58. Morselli E, Tasdemir E, Maiuri MC, et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7: 3056-61.
59. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10: 676-87.
60. Crighton D, ÓPreyl JO, Bell HS, Ryan KM. p73 regulates DRAMindependent autophagy that does not contribute to programmed cell death. Cell Death Differ 2007; 14: 1071-9.
61. Sarkar S, Ravikumar B, Rubinsztein C. Autophagic clearance of aggregate-prone proteins associated with neurodegeneration. Meth Enzymol 2009; 453: 83-110.
62. Cheung ZH, Ip NY. Autophagy deregulation in neurodegenerative diseases-recent advances and future perspectives. J Neurochem 2011; 118: 317-25.
63. Nishino I. Autophagic vacuolar myophaties. Curr Neurol Neurosci Rep 2003; 3: 64-9.
64. Cuervo AM. Autophagy: in sickness and in health. Trends Cell Biol 2004; 14: 70-7.
65. Morselli E, Galluzzi L, Kepp O, et al. Anti-and pro-tumor functions of autophagy. Biochim Biophys Acta 2009; 1793: 1524-32.
66. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-52.
67. KondoY, Kanzawa T, Sawaya, Kondo S. The role of autophagy in cancer development and response to therapy. Nature Rev Cancer 2005; 5: 726-34.
68. Hippert MM, O'Toole PS, Thorburn A Autophagy in cancer: Good, bad, or both? Cancer Res 2006; 66: 9349-51.
69. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-7.
70. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15: 5308-16.
71. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, et al. The autophagic tumor stroma model of cancer or "battery-operated tumor growth". A simple solution to the autophagy paradox. Cell Cycle 2010 9: 4297-306.
72. Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Lett 2010; 584: 1427-35.
73. Debnath J. The multifaceted roles of autophagy in tumorsimplications for breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 173-87.
74. Ekbom A, Helmick C, Zack M, Adami H. Increased risk of largebowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336: 357-9.
75. ÓConnor PM, Lapointe TK, Beck PL, et al. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1411-20.
76. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991; 325: 928-37.
77. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12(Suppl 1): S3-S9.
78. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: Genetics and immunology. Curr Gastroenterol Rep 2008; 10: 568-75.
79. Ishiara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y. Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol 2009; 44: 1097-108.
80. Kaser A, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 2011; 140: 1738-47.
81. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-35.
82. Stappenbeck TS, Rioux JD, Mizoguchi A, et al. Crohn disease. A current perspective on genetics, autophagy and immunity. Autophagy 2011; 7: 355-74.
83. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-16.
84. Huett A, Goel G, Xavier RJ. A systems biology viewpoint on autophagy in health and disease. Curr Opin Gastroenterol 2010; 26: 302-9.
85. Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008; 134: 743-56.
86. Hampe A, Franke P, Rosential A, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-11.
87. Cummings JRF, Pathan S, et al. Confirmation of the role of ATG16L1 as a Crohn's disease susceptibility gene. Inflamm Bowel Dis 2007; 13: 941-6.
88. McCarroll SA, Huett A, Kuballa SD, et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008; 40: 1107-12.
89. Singh SB, Davis. S, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006; 313: 1438-41.
90. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456: 264-8.
91. Cadwell K, Liu J, Brown S, et al. A unique role for autophagy and Atg16L1 in Paneth cells in murine and human intestine. Nature 2008; 456: 259-63.
92. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-7.
93. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62.
94. Saleh M. The machinery of Nod-like receptors: refining the paths to immunity and cell death. Immunol Rev 2011; 243: 235-46.
95. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 2007; 315: 1398-401.
96. Sanjuan MA, Dillon CP, Tait SW, et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 2007; 450: 1253-7.
97. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
98. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
99. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-7.
100. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
101. Stephenson LM, Miller BC, Ng A, et al. Identification of Atg5-dependent transcriptional changes and increases in mitochondrial mass in Atg5-deficient T lymphocytes. Autophagy 2009; 5: 625-35.
102. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci USA 2009; 106: 2770-5.
103. Bekpen C, Marques-Bonet T, Alkan C, et al. Death and resurrection of the human IRGM gene. PLoS Genet 2009; 5: e1000403.
104. Deretic V, Levine B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009; 5: 527-49.
105. Bafica A, Feng CG, Santiago HC, et al. The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflamma tory cytokine production and prevents endotoxemia. J Immunol 2007; 179: 5514-22.
106. Brest P, Corcelle EA, Cesaro A, et al. Autophagy and Crohn's disease: at the crossroads of infection, inflammation, immunity, and cancer. Curr Mol Med 2010; 10: 486-502.
107. Crisan TO, Plantinga TS, van de Veerdonk FL, et al. Inflammasome-independent modulation of cytokine response by autophagy in human cells. PLoS One 2011; 6: e18666.
108. Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137: 1062-75.
109. Chen Q, Xie W, Kuhn DJ, et al. Targeting the p27 E3 ligase SCF (Skp2) results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-9.
110. Barré B, Perkins ND. The Skp2 promoter integrates signaling through the NF-κB, p53, and Akt/GSK3β pathways to regulate autophagy and apoptosis. Mol Cell 2010; 38: 524-38.
111. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124: 1265-76.
112. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5: 104-12.
113. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005; 54: 1182-93.
114. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753-66.
115. Kirkegaard K, Taylor MP, Jackson WT. Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol 2004; 2: 301-14.
116. Ramjeet M, Hussey S, Philpott DJ, Travassos LH. 'Nodophagy': New crossroads in Crohn disease pathogenesis. Gut Microbes 2010; 1: 307-15.
117. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Tolllike receptors control autophagy. EMBO J. 2008; 27: 1110-21.
118. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007; 27: 135-44.
119. Deretic V. Multiple regulatory and effector roles of autophagy in immunity. Curr Opin Immunol 2009; 21: 53-62.
120. Zhou D, Li P, Lin Y, et al. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 2005; 22: 571-81.
121. Dengjel J, Schoor O, Fischer R, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA 2005; 102: 7922-7.
122. Lee HK, Mattei LM, Steinberg BE, et al. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity 2010; 32: 227-39.
123. Schmid D, Pypaert M, Münz C. MHC class II antigen loading compartments continuously receive input from autophagosomes. Immunity 2007; 26: 79-92.
124. Schmid D, Münz C. Innate and adaptive immunity through autophagy. Immunity 2007; 27: 11-21.
125. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004; 15: 1101-11.
126. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298-306.
127. Ouellette AJ. Paneth cells and innate immunity in the crypt microenvironment. Gastroenterology 1997; 113: 1779-84.
128. Ganz T. Paneth cells-guardians of the gut cell hatchery. Nat Immunol 2000; 1: 99-100.
129. Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol 2008; 22: 391-409.
130. Cadwell K, Patel KK, Komatsu M, Virgin HW 4th, Stappenbeck TS. A common role for Atg16L1, Atg5 and Atg7 in small intestinal Paneth cells and Crohn disease. Autophagy. 2009; 5: 250-2.
131. Kaser A, Blumberg RS. Endoplasmic reticulum stress in the intestinal epithelium and iflammatory bowel disease. Semin Immunol 2009; 21: 156-163.
132. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
133. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008; 8: 663-74.
134. Hetz C, Glimcher L. Fine-tuning of the unfolded protein response: assembling the IRE1alpha interactome. Mol. Cell 2009; 35: 551-61.
135. Hetz C. ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage, Antioxid Redox Signal 2007; 9: 2345-55.
136. Hetz C, Glimcher L. The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology, Trends Cell Biol 2008; 18: 38-44.
137. Zhang K, Kaufman R. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008; 454: 455-62.
138. Rath E, Haller D. Inflammation and cellular stress: a mechanistic link between immune-mediated and metabolically driven pathologies. Eur J Nutr 2011; 50: 219-33.
139. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-89.
140. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107: 881-91.
141. Calfon M, Zeng H, Urano F, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002; 415: 92-96.
142. Lee K, Tirasophon W, Shen X, et al. IRE1-mediated unconventional mRNA splicing and S2Pmediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev 2002; 16: 452-66.
143. Lee A, Iwakoshi N, Glimcher L. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response, Mol Cell Biol 2003; 23: 7448-59.
144. Hetz C, Glimcher L. The UPRosome and XBP-1: mastering secretory cell function. Curr Immunol Rev 2008; 4: 1-10.
145. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946-51.
146. Hollien J, Weissman J. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 2006; 313: 104-7.
147. Han D, Lerner AG, Vande Walle L, et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 2009; 138: 562-75.
148. Nishitoh H, Matsuzawa A, Tobiume K, et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002; 16: 1345-55.
149. Urano F, Wang X, Bertolotti A, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000; 287: 664-6.
150. Kaser A, Blumberg RS. Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol 2010; 3: 11-6.
151. Kaser, A. Martínez-Naves E., Blumberg R. Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2010, 26: 318-26.
152. Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem 1998; 273: 33741-9.
153. Kokame K, Kato H, Miyata T. Identification of ERSE-II, a new cis-acting element responsible for the ATF6-dependent mammalian unfolded protein response. J Biol Chem 2001; 276: 9199-205.
154. Yamamoto K, Sato T, Matsui T, et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell 2007; 13: 365-76.
155. Bernales S, McDonald KL, Walter P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol 4: e423, 2006.
156. Ogata M, Hino S, Saito A, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006; 26: 9220-31.
157. Yorimitsu T, Nair U, Yang Z, Klionsky DJ. Endoplasmic Reticulum stress triggers autophagy. J Biol Chem 2006; 281: 30299-304.
158. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43: 67-93.
159. Ding WX, Ni HM, Gao W, et al. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem 2007: 282; 4702-10.
160. Kouroku Y, Fujita E, Tanida I, et al. ER stress (PERK/elF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ 2007; 14: 230-39.
161. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu. Endoplasmic reticulum stress mediates radiation-induced autophagy via PERKelF2α in caspase-3/7 deficient cells. Oncogene 2010; 29: 3241-51.
162. Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitinproteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007b; 171: 513-24.
163. Yorimitsu T, Klionsky DJ. Endoplasmic reticulum stress: a new pathway to induce autophagy. Autophagy 2007; 3: 160-2.
164. Høyer-Hansen M, Jäättelä M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ 2007; 14: 1576-82.
165. Sakaki K, Wu J, Kaufman RJ. Protein kinase Cθ is required for autophagy in response to stress in the endoplasmic reticulum. J Biol Chem 2008; 283: 15370-80.
166. Stephen M, Schleicher, Moretti L, Varki V, Lu B. Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches. Drug Resist Updat 2010; 13: 79-86.
167. Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in apoptosis and autophagy: role of BCL-2 protein family. Oncogene 2008; 27: 6419-33.
168. Todde V, Veenhuis M., van der Klei I. Autophagy: principles and significance in health and disease. Biochim Biophys Acta 2009; 1972: 3-13.
169. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-69.
170. Andresen L, Jorgensen VL, Perner A, Hansen A, Eugen-Olsen J, Rask-Madsen J. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 2005; 54: 503-9.
171. Hu P, Han Z, Couvillon AD, Kaufman RJ, Exton JH. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol 2006; 26: 3071-84.
172. Deng J, Lu PD, Zhang Y, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Bio 2004; 24: 10161-8.
173. Shkoda A, Ruiz P, Daniel H, et al. Interleukin 10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 2007 132: 190-207.
174. Pahl HL, Baeuerle PA. A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B. EMBO J 1995; 14: 2580-8.
175. McGuckin MA, Eri RD, Das I, Lourie R, Florin TH. ER stress and the unfolded protein response in intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 298: G820-32.
176. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
177. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol 2008; 1: 183-97.
178. McVay LD, Keilbaugh SA, Wong TM, et al. Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis. J Clin Invest 2006; 116: 2914-23.
179. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307: 1904-9.
180. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 2008; 105: 20858-63.
181. Zhao F, Edwards R, Dizon D, et al. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/-mice. Dev Biol 2010; 338: 270-9.
182. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6: 551-7.
183. Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11: 76-83.
184. Levine SJ, Larivee P, Logun C, Angus CW, Ognibene FP, Shelhamer JH. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Mol Biol 1995; 12: 196-204.
185. Enss ML, Cornberg M, Wagner S, et al. Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 2000; 49: 162-9.
186. Louahed J, Toda M, Jen J, et al. Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol 2000; 22: 649-56.
187. Kim YD, Jeon JY, Woo HJ, et al. SH. Interleukin-1beta induces MUC2 gene expression and mucin secretion via activation of PKCMEK/ ERK, and PI3K in human airway epithelial cells. J Korean Med Sci 2002; 17: 765-71.
188. Iwashita J, Sato Y, Sugaya H, Takahashi N, Sasaki H, Abe T. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogenactivated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003; 81: 275-82.
189. Li JD, Dohrman AF, Gallup M, et al. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci USA 1997; 94: 967-72.
190. Dohrman A, Miyata S, Gallup M, et al. Mucin gene (MUC2 and MUC5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1998; 1406: 251-9.
191. Lemjabbar H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 2002; 8: 41-6.
192. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. Induction of MUC2 and MUC5AC mucin by factors of the epidermal growth factor family is mediated by EGF-R/Ras/Raf/MAPK signaling cascade and Sp1. J Biol Chem 2002; 277: 32258-67.
193. Gaudier E, Jarry A, Blottiere HM, et al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1168-74.
194. Hokari R, Lee H, Crawley SC, et al. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am J Physiol Gastrointest Liver Physiol 2005; 289: G949-59.
195. El Homsi M, Ducroc R, Claustre J, et al. Leptin modulates the expression of secreted and membrane-associated mucins in colonic epithelial cells by targeting PKC, PI3K, and MAPK pathways. Am J Physiol Gastrointest Liver Physiol 2007; 293: G365-73.
196. Lee SY, Lee MS, Cherla RP, Tesh VL. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell Microbiol 2008; 10: 770-80.
197. Xue X, Piao JH, Nakajima A, et al. Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem 2005; 280: 33917-25.
198. Bertolotti A, Wang X, Novoa I, et al. Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. J Clin Invest 2001; 107: 585-93.
199. Heazlewood CK, Cook MC, Eri R, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008; 5: e54.
200. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402: 672-6.
201. Liang C, Feng P, Ku B, et al. Autophagic and tumour suppressor activity of a novel Beclin-1-binding protein UVRAG. Nat Cell Biol 2006; 8: 688-99.
202. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/δ716 Cdx2+/-compound mutant mice. Nat Genet 2003; 35: 323-30.
203. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apcrrrrrr716 777777mice. Proc Natl Acad Sci USA 2008; 105: 13544-9.
204. Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, Wolff RK. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: MTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 2010; 31: 1604-1611.
205. Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 2010; 210: 767-76, 776-8.
206. Gulhati P, Cai Q, Li J, et al. Targeted inhibition of Mammalian Target of Rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009; 15: 7207-16.
207. Zhang YJ, Dai Q, Sun DF, et al. mTOR Signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 2009a; 16: 2617-28.
208. Ekstrand AI, Jönsson M, Lindblom A, Borg A, Nilbert M. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Familial Cancer 2010; 9: 125-9.
209. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-68.
210. Rodrigues NR, Rowan A, Smith MEF, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-9.
211. Scherz-Shouval R, Weidberg H, Gonen C, Wilder S, Elazar Z, Oren M. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci USA 2010; 107: 18511-6.
212. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signalling pathways. J Biol Chem 2002; 277: 25226-32.
213. Leverve XM, Guigas B, Detaille D, et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29: 6S88-94.
214. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-52.
215. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5.
216. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-8.
217. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
218. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-5.
219. Baba Y, Nosho K, Shima K, et al. Prognostic significance of AMPactivated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 2010; 103: 1025-33.
220. Stünkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2: 1360-8.
221. Nosho K, Shima K, Irahara N, et al. SIRT1 histonedeacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009; 22: 922-32.
222. Kabra N, Li Z, Chen L, et al. Sirt1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009; 284: 18210-7.
223. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010; 16: 196-201.
224. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008; 3: e2020.
225. Tetsu O, McCormick F. [-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
226. Ge X, Jin Q, Zhang F, Yan T, Zhai Q. PCAF acetylates [-catenin and improves its stability. Mol Biol Cell 2009; 20; 419-27.
227. Holloway KR, Calhoun TN, Saxena M, et al. SIRT1 regulates Dishevalled proteins and promotes transient and constitutive Wnt signalling. Proc Natl Acad Sci USA 2010; 107: 9216-21.
228. Back JH, Rezvani HR, ZhunY, et al. Cancer cell survival following DNA damage-mediated premature senescence is regulated by Mammalian Target of Rapamycin (mTOR)-dependent inhibition of Sirtuin 1. J Biol Chem 2011; 286: 19100-8.
229. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 2: 815-22.
230. Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008; 57: 1294-6.
231. Deng L, Zhou JF, Sellers RS, et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycindependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol 2010; 176: 952-67.
232. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010; 6: 322-9.
233. Liu B, Cheng Y, Liu Q, Bao JK, Yang JM. Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin 2010; 31: 1154-64.
234. Turcotte S, Giaccia AJ. Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol 2010; 22: 246-51.
235. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 15; 7: 54-66.
236. Chen N, Karantza V. Autophagy as a therapeutic target in cancer. Cancer Biol Ther 2011; 11: 157-68.
237. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol 2011; 7: 9-17.
238. Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther 2011; 131: 130-41.
239. Liu JJ, Lin M, Yu JY, Liu B, Bao JK. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett 2011; 300: 105-14.
240. Meschini S, Condello M, Lista P, Arancia G. Autophagy: Molecular mechanisms and their implications for anticancer therapies. Curr Cancer Drug Targets 2011; 11: 357-79.
241. Sui X, Jin L, Huang X, Geng S, He C, Hu X. p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment. Autophagy 2011; 7: 565-71.
242. Wu L, Yan B. Discovery of small molecules that target autophagy for cancer treatment. Curr Med Chem 2011; 18: 1866-73.
243. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther 2011; 11: 169-76.
244. Shacka JJ, Klocke BJ, Roth KA. Autophagy, bafilomycin, cell death: the "a-B-cs" of plecomacrolide-induced neuroprotection. Autophagy 2006; 2: 228-30.
245. Seglen PO, Gordon PB. 3-Methyladenine: Specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA 1982; 79: 1889-2.
246. Blommaart EFC, Krause U, Schellens JPM, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 1997; 243: 240-6.
247. Reddy BS, Watanabe K, Weisburger JH, Wynder EL. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res 1977; 37: 3238-42.
248. Payne CM, Crowley-Skillicorn C, Holubec H, et al. Deoxycholate, an endogenous cytotoxin/genotoxin, induces the autophagic stresssurvival pathway: implications for colon carcinogenesis. J Toxicol 2009; 2009: 785907.
249. Wu YC, Wu WKK, Li Y, et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 2009; 382: 451-6.
250. Zheng Y, Zhao YL, Deng X, et al. Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest 2009; 27: 286-92.
251. Sasaki K, Tsuno NH, Tsurita G, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010; 10: 370.
252. Høyer-Hansen M, Jäättelä M. Autophagy: an emerging target for cancer therapy. Autophagy 2008; 4: 574-80.
253. Bauvy C, Gane P, Arico S, Codogno P, Ogier-Denis E. Autophagy delays sulindac sulphide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res 2001; 268: 139-49.
254. Han J, Hou W, Goldstein LA, et al. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008; 283: 19665-77.
255. Sato K, Tsuchihara S, Fujii M, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 2007; 67: 9677-84.
256. Nishikawa T, Tsuno NH, Okaji Y, et al. Inhibition of autophagy potentiates sulphorane-induced apoptosis in human colon cancer cells. Ann Surg Oncol 2010; 17: 592-602.
257. Li J, Hou N, Faried A; Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010; 46: 1900-9.
258. Li J, Hou N, Faried A; Tsutsumi S, Takeuchi T, Kuwano H. Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol 2009; 16: 761-71.
259. Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 2010; 126: 2457-68.
260. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer 2009; 8: 100.
261. Lynn A, Collins A, Fuller Z, Hillman K, Ratcliffe B. Cruciferous vegetables and colorectal cancer. Proc Nutr Soc 2006; 65: 135-44.
262. Higdon JV, Delage B, Williams DE, Dashwood RD. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007; 55: 224-36.
263. Navarro SL, Li F, Lampe JW. Mechanisms of action of isothiocyanates in cancer chemoprevention: an update. Food Funct 2011; DOI: 10.1039/C1FO10114E.
264. Thyagarajan A, Jedinak A, Nguyen H, et al. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr Cancer 2010; 62: 630-40.
265. Ellington AA, Berhow M, Singletary KW. Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins. Carcinogenesis 2005; 26: 159-67.
266. Johnson SM, Gulhati P, Arrieta I, et al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signalling. Anticancer Res 2009; 29: 3185-90.
267. Kim Y, Oh S, Yun HS, Oh S, Kim SH. Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett Appl Microbiol 2010; 51: 123-30.
268. Lee YK, Lee WS, Kim GS, Park OJ. Anthocyanins are novel AMPKA1 stimulators that suppress tumor growth by inhibiting mTOR phosphorylation. Oncol Rep 2010; 24: 1471-7.
269. Chung HJ, Rhee HK, Lee SK, Park Choo HY. Antitumor effects of a novel benzonaphthofurandione derivative (8e) on the human colon cancer cells in vitro and in vivo through cell cycle arrest accompanied with the modulation of EGFR and mTOR signaling. Chem Biol Interact 2011; 193: 43-9.
270. Lee MS, Cha EY, Sul JY, Song IS, Kim JY. Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. Phytother Res 2011; 25: 833-837.
271. Xie CM, Chan WY, Yu S, Zhao J, Cheng CHK. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med 2011; 51: 1365-75.
272. Yuk JM, Shin DM, Song KS, et al. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 2010; 6: 46-60.
273. Canals D, Perry DM, Jenkins RW, Hannun YA. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 2011; 163: 694-712
274. Selzner M, Bielawska A, Morse MA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61: 1233-40.
275. Nemoto S, Nakamura M, Osawa Y, et al. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 2009; 284: 10422-32.
276. Xiong HY, Guo XL, Bu XX, et al. Autophagic cell death induced by 5-FU in Bax or PUMA deficient human colon cancer cell. Cancer Lett 2010; 288: 68-74.
277. Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the Mammalian Target of Rapamycin (mTOR) in cancer therapy: Lessons from past and future perspectives. Cancers 2011; 3: 2478-500.
278. Zhang YJ, Zhao SL, Tian XQ, et al. Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer. Int J Colorectal Dis 2009; 24: 629-39.
279. Wagner M, Roh V, Strehlen M, et al. Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. J Gastrointest Surg 2009; 13: 1781-90.
280. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 98: 923-30.
281. Tabernero J, Rojo F, Calvo E, et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-10.
282. Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010; 40: 732-8.
283. Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010; 40: 17-23.
284. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
285. Yang Q, Guan KL. Expanding mTOR signalling. Cell Res 2007; 17: 666-81.
286. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 2010; 9: 57.
287. Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246-56.
288. Bhagwat SV, Gokhale PC, Crew AP, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: Distinct from rapamycin. Mol Cancer Ther 2011; 10: 1394-406.
289. Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6: 24-35.
290. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e38.
291. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem 2009; 284: 8023-32.
292. Zhang YJ, Duan Y, Zheng XFS. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 2011; 16: 325-31.
293. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive Mammalian Target of Rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-98.
294. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891-906.
295. Firbley A, Zeng O, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stressreactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24: 9695-704.
296. Ustundag Y, Bronk SF, Gores GJ. Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol 2007; 13: 851-7.
297. Pyrko P, Kardosh A, Wang W, Xiong W, Schönthal AH, Chen TC. HIV protease inhibitors nelfinavir and atazanavir induce glioblastoma cell death by triggering endoplasmic reticulum (ER) stress. Cancer Res 2007; 67: 10920-8.
298. Harada M, Hanada S, Toivola DM, Ghori N, Omary MB. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Hepatology 2008; 47: 2026-35.
299. Fels DR, Ye J, Segan AT, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 2008; 68: 9323-30.
300. Ding WX, Ni HM, Gao W, et al. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 2009; 8: 2036-45.
301. Bruserud O, Stapnes C, Ersvaer E, Gjerten BT, Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007; 8: 388-400.
302. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008; 68: 2557-60.
303. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-5.
304. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 2009; 8: 342-9.
305. Carew JS, Medina EC, Esquivel II JA, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010; 14: 2448-59.
306. Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008; 1: 369-75.
307. Hwang JT, Kim YM, Surh YJ, et al. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res 2006; 66: 10057-63.
308. Hwang JT, Ha J, Park IJ, et al. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 2007; 247: 115-21.
309. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-86.
310. Tomimoto A, Endo H, Sugiyama, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008; 99: 2136-41.
311. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010; 49: 662-71.
312. Hosono K, Endo H, Takahashi H, Sugiyama M, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010; 3: 1077-83.
313. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9: 33.
314. Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012; 133: 108-15.
315. Dowling RO, Niraula S, Stambolic V, Goodwin PJ. Metformin in Cancer: Translational Challenges. J Mol Endocrinol 2012; doi: 10.1530/JME-12-0007.
316. Habeeb BS, KitayamaJ, Nagawa H. Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 2011; 102: 999-1006.